- Dundee Corporation (DC.A) announced that TauRx Pharmaceuticals unveiled Phase 3 results from its Alzheimer’s disease study, LUCIDITY
- TauRx appointed Dr. Richard Stefanacci as the company’s new Chief Medical Officer
- Jonathan Goodman, President and Chief Executive Officer of Dundee Corporation, sat down with Simon Druker to discuss the news
- Dundee holds 1,015,008 shares in TauRx, representing an undiluted interest of 3.5 per cent in the company
- Dundee Corporation is an active investor focused on delivering long-term, sustainable value through investments in the mining sector
- Dundee (DC.A) opened trading at $1.30 per share
Dundee Corporation (DC.A) announced that TauRx Pharmaceuticals unveiled Phase 3 results from its Alzheimer’s disease study, LUCIDITY.
TauRx announcement highlights:
- For people with early Alzheimer’s (MCI), HMTM treatment resulted in sustained improvement in cognition over the pre-treatment baseline and normalization of brain atrophy to a rate similar to healthy individuals;
- For people with mild to moderate Alzheimer’s, HMTM stabilized cognition and function and reduced the rate of brain atrophy compared to historical matched individuals with AD;
- HMTM is an oral drug with a strong safety profile, having no risk of amyloid-related imaging abnormalities;
- TauRx will present the Phase 3 findings at the Clinical Trials in Alzheimer’s Disease (CTAD) conference on Wednesday, November 30th, 2022, in San Francisco.
TauRx appointed Dr. Richard Stefanacci as the company’s new Chief Medical Officer. Working alongside advisors in the UK, U.S. and Canada, Dr. Stefanacci will assist with regulatory submissions.
Jonathan Goodman, President and Chief Executive Officer of Dundee Corporation, sat down with Simon Druker to discuss the news.
“Alzheimer’s is a terrible disease that has impacted far too many people globally, including my own family. I am personally very encouraged by this news, as, from our perspective, it gives great hope that we might be finally turning the tide in our fight against this disease. We understand that TauRx has some additional obstacles to overcome to obtain the regulatory approvals needed to bring its drug to market. It has the potential to have a significant positive impact on both the value of TauRx and Dundee Corporation. We are extremely pleased that LUCIDITY has demonstrated effectiveness for people afflicted with mild to moderate Alzheimer’s while retaining a strong safety profile. We are further encouraged by the fact that HMTM is administered orally without the need for expensive monitoring, providing advantages over more expensive and less safe and effective approved alternatives available to patients today. This is a very exciting time for both TauRx and Dundee Corporation as we believe this is a milestone that will pave the way for eventual commercial success.”
Dundee holds 1,015,008 shares in TauRx, representing an undiluted interest of 3.5 per cent in the company. Dundee Corporation determined that the fair value of its investment in TauRx, on June 30, 2022, was $36.2 million.
Dundee Corporation is an active investor focused on delivering long-term, sustainable value through investments in the mining sector.
Dundee (DC.A) opened trading at $1.30 per share.
